Simple Summary Immune checkpoint inhibitor (ICI) therapy has recently become the
standard treatment for advanced hepatocellular carcinoma (HCC); however, clinical …

Despite advances in cancer treatment, hepatocellular carcinoma (HCC), the most common
form of liver cancer, remains a major public health problem worldwide. The immune …

Over the last several decades, a number of new treatment options for patients with
hepatocellular carcinoma (HCC) have been developed. While treatment decisions for some …

Simple Summary Hepatocellular carcinoma (HCC) is a common cause of cancer-related
deaths worldwide. During the early stages of the disease, HCC can be treated with surgery …

Objective Selecting interventions for patients with solitary hepatocellular carcinoma (HCC)
remains a challenge. Despite gross classification being proposed as a potential prognostic …

Introduction: While combination of stereotactic body radiotherapy (SBRT) and
immunotherapy are promising, their efficacy and safety have not been compared with SBRT …

Simple Summary Hepatocellular carcinoma (HCC) is one of the most prevalent and
devastating malignancies worldwide. An ongoing phase-II clinical trial assesses the efficacy …

The use of immune checkpoint inhibitors (ICIs) targeting PD-L1/PD-1 and CTLA-4 has
transformed the oncology practice of hepatocellular carcinoma. However, only 25–30% of …

As the major malignant tumors in the chest, non-small cell lung cancer (NSCLC) and
esophageal cancer (EC) bring huge health burden to human beings worldwide. Currently …

Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing
approximately 85% of cases. The diagnosis is often made in the middle and late stages …